Active Drug Safety Monitoring and Management (aDSM) Program
The Department of Health (DOH) Disease Prevention and Control Bureau – National Tuberculosis Control Program (DPCB-NTP) has been implementing the use of Standard Shorter Treatment Regimen (SSTR) which reduces the treatment duration for patients with multi-drug resistant tuberculosis (MDR-TB) from eighteen (18) months to nine (9) months. Moreover, the DPCB-NTP has already introduced the use of new anti-TB drugs and repurposed drugs for patients with drug-resistant (DR-TB) in the country. These interventions in TB management require active surveillance as part of pharmacovigilance for patients under MDR-TB and extensively Drug-Resistant TB (XDR-TB) treatment. In 2015, the Active Tuberculosis Drug-Safety Monitoring and Management (aDSM) Framework for Implementation of the World Health Organization (WHO) recommended immediate action for countries to adopt aDSM to complement the aforementioned interventions of the TB program. The implementation of aDSM is an integral component of the comprehensive package of TB services that will be provided to all patients with TB using a new anti-TB drug, repurposed drug, or a new regimen. This is aligned with the goal of the “Universal Health Care Act” to provide comprehensive quality and cost-effective health care services for all.
Since the Pharmaceutical Division (PD) is in charge of the monitoring of the utilization of the DOH public health program (PHP) medicines in the different health facilities, the office has included pharmacovigilance of PHPs in its operations, including the implementation of the aDSM program. The DOH-hired public health pharmacists who will assist in collecting and consolidating reports of Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs) in areas with no internet connection and encode the data in to Pharmacovigilance Monitoring System (PViMS). PViMS is a web-based monitoring tool, which enables the implementation of active surveillance activities in low- and middle-income countries (LMICs) by addressing the entire data collection, data analysis, and reporting process. These reports will then be submitted by the DOH-PD to the Food and Drug Administration (FDA) for causality assessment and analysis of reports.
Frequently asked questions
News and updates regarding the Active Drug Safety Monitoring and Management Program
Telephone Number: 02-8757734 Loc. 253
Address: 4th Floor, Philippine Blood Center, Lung Center Compound, Quezon Avenue, Quezon City
Email Address: firstname.lastname@example.org